SEP 03, 2020 7:30 AM PDT

A Low-Cost COVID-19 Treatment, Made in Horses

WRITTEN BY: Tara Fernandez

Researchers in Costa Rica are turning to horses as an unlikely source of potential therapeutic antibodies against COVID-19. If these equine immunoglobulins prove to be effective in humans, they could fill a desperately needed gap in accessible pharmaceuticals to help patients with severe, life-threatening cases of COVID-19. Critically, horse antibodies would be significantly cheaper to mass-produce than human antibodies.

So far, preliminary studies in the lab show that the horse antibodies against SARS-CoV-2 were able to kill the virus. The Clodomiro Picado Institute first started using horses to create antibodies as antidotes to venomous snake and spider bites. Horses are exposed to minute amounts of these venoms and over time, build up resistance to them by generating venom-targeting antibodies. Equine antivenoms manufactured at the institute save the lives of over 500 people in Costa Rica annually, and thousands more in other countries.

The team is now channeling their expertise in equine immunology into generating COVID-19 treatments, by swapping venom injections for the spike protein of SARS-CoV-2. This work has been spurred by previous successes in generating antibodies against other pathogenic viruses such as influenza and a related coronavirus that causes the Middle East Respiratory Syndrome, or MERS.

Alape Girón, lead researcher of the COVID-19 project said, “The idea behind the antibody therapy for patients with COVID-19 is similar to that of treating patients suffering from snakebite poisoning.”

“We want to generate specific antibodies against viral structures in horses, purify the antibodies and give them to patients who are starting to fight the infection but whose immune system still does not produce enough antibodies to clear the viral particles, ” he explained.

The next steps for the team include an accelerated clinical trial to test their efficacy in 26 COVID patients, scheduled to commence shortly. Should the results turn out to be promising, more comprehensive clinical studies involving larger cohorts will be conducted. A single vial of horse antibodies, which target multiple sites on the coronavirus, will cost an estimated $100 to manufacture, around ten-fold cheaper than what it costs to make a human monoclonal equivalent.

 

 

Source: Scientific American.


 

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
JUL 19, 2021
Health & Medicine
The Pandemic and Fewer Asthma Attacks?
JUL 19, 2021
The Pandemic and Fewer Asthma Attacks?
Asthma sufferers: Quarantine during the pandemic may have not only helped you avoid COVID but more asthma attacks as wel ...
AUG 13, 2021
Cancer
Ultrasound Triggers Immunotherapy to Destroy Tumors
AUG 13, 2021
Ultrasound Triggers Immunotherapy to Destroy Tumors
An immunotherapy engineered to be triggered by ultrasound beams significantly slows the growth of cancerous tumors in mi ...
AUG 30, 2021
Cancer
A Hot Approach to CAR T Cells
AUG 30, 2021
A Hot Approach to CAR T Cells
Immunotherapy, a type of treatment that targets a patient’s immune system to enhance the natural ability to attack ...
SEP 03, 2021
Cell & Molecular Biology
Is a Venom-Like Molecule Involved in COVID-19 Mortality?
SEP 03, 2021
Is a Venom-Like Molecule Involved in COVID-19 Mortality?
Scientists have sought to learn more about why some people get severe COVID-19 while others have only mild cases. We kno ...
SEP 12, 2021
Coronavirus
Real-World, Post-Delta COVID-19 Vaccine Data & Potential Treatment
SEP 12, 2021
Real-World, Post-Delta COVID-19 Vaccine Data & Potential Treatment
New research may have identified a potential treatment or preventive medication for SARS-CoV-2 and other viral infection ...
SEP 14, 2021
Drug Discovery & Development
A novel drug that targets the removal of pathogenic antibodies in myasthenia gravis
SEP 14, 2021
A novel drug that targets the removal of pathogenic antibodies in myasthenia gravis
Myasthenia gravis is a chronic autoimmune disorder characterized by muscle weakness and fatigue. The disorder leads to a ...
Loading Comments...